Treatment Selection for Multiple Myeloma: Using Recent Advances to Optimize Care
Release Date: March-14-12
Credit Expiration Date: March-14-13
The intended audience for this educational activity is physicians (including oncologists and hematologists), oncology nurses, and other health care professionals interested or involved in the treatment of patients with multiple myeloma.
Physicians: 1.0 AMA PRA Category 1 Credits TM
Nurses: 1.0 contact hours
NOTE: This activity was presented as a live grand rounds series between September 2011 and January 2012. Participants who received credit for attending any of the live presentations are not eligible to receive credit for this online release.
Multiple myeloma, a bone marrow cancer that is often accompanied by bone pain, fractures, infections, renal failure, immunodeficiency, weakness, and confusion, is the second most prevalent hematological malignancy in the United States and constitutes about 1-2% of all cancers nationwide. Treatment is typically administered based on a number of patient factors such as disease stage, level of function, quality of life, and presence of comorbidity. With conventional treatment, the median survival is 3-4 years, which may be extended to 5-7 years or longer with advanced treatments. An abundance of treatment strategies, however, has led to confusion among oncologists regarding the selection of optimal therapy for each patient.
Physicians who are unaware of recent clinical-trial data are at risk of utilizing suboptimal therapy in their patients, potentially resulting in disease progression and increased mortality. Because there is a lack of consensus regarding best treatment, and because there are numerous patient factors that can influence standards of care, the ability to select the most appropriate therapy in each patient is one of the most challenging aspects of multiple myeloma care. Novel agents and aggressive interventions have led to recent changes in guideline recommendations. With an improved understanding of best strategies in multiple myeloma care, oncology clinicians can help lessen the burden of illness and improve the lives of the patients in their care.
Parameswaran Hari, MBBS, MD, MRCP, MS
Associate Professor of Medicine
Section Head and Director, Adult BMT Program
Division of Hematology and Oncology
Medical College of Wisconsin
Amit K. Verma, MBBS
Associate Professor of Medicine
Albert Einstein College of Medicine
Jack and Pearl Resnick Campus
The “Conflict of Interest Disclosure Policy” of Albert Einstein College of Medicine requires that faculty participating in any CME activity disclose to the audience any relationship(s) with a pharmaceutical, product, or device company. Any presenter whose disclosed relationships prove to create a conflict of interest with regard to their contribution to the activity will not be permitted to present. Albert Einstein College of Medicine and Medical Communications Media, Inc. staff have no conflicts of interest with commercial interests related directly or indirectly to this educational activity.
Albert Einstein College of Medicine also requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product not yet approved for use in the United States.
Dr. Hari has no disclosures.
Dr. Verma has no disclosures.
The staff of CCME of Albert Einstein College of Medicine have no disclosures to report with any commercial interests other than the following:
Steven Jay Feld, or a member of his household, own securities in: Bioheart Inc.; Chelsea Therapeutics, Inc.; and Pharmacopeia, Inc.
Kathleen Hines (MCM, Inc. medical editor) has no disclosures.
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint sponsorship of Albert Einstein College of Medicine of Yeshiva University, Montefiore Medical Center and Medical Communications Media, Inc. Albert Einstein College of Medicine of Yeshiva University is accredited by the ACCME to provide continuing medical education for physicians.
Albert Einstein College of Medicine of Yeshiva University designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s) TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Credit is awarded to participants who score 60% or better on the post-test.
This activity will take approximately 60 minutes to complete.
Montefiore Learning Network is an approved provider of continuing nursing education by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
This activity is awarded 1.0 contact hours and is assigned approval code 7UZLNN-PRV-09-193.
This activity is supported by an educational grant from Millennium: The Takeda Oncology Company.
Presented by Albert Einstein College of Medicine & Montefiore Medical Center, Center for Continuing Medical Education and Medical Communications Media, Inc.
The opinions expressed in these educational activities are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Albert Einstein College of Medicine & Montefiore Medical Center, Center for Continuing Medical Education, or Millennium: The Takeda Oncology Company. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.